Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

165.71 +2.72 (+1.67%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 883,430
Open 162.32
Bid (Size) 165.50 (100)
Ask (Size) 165.77 (100)
Prev. Close 162.99
Today's Range 162.15 - 166.23
52wk Range 34.00 - 166.50
Shares Outstanding 106,313,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Can Revolution Medicines Be a Game-Changer Stock? ↗
This company's potential pancreatic cancer blockbuster could be a watershed moment. 
Via The Motley Fool
News headline image
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗
Can the drugmaker justify its valuation? 
Via The Motley Fool

Performance

YTD
+109.7%
+109.7%
1 Month
+9.3%
+9.3%
3 Month
+71.5%
+71.5%
6 Month
+105.6%
+105.6%
1 Year
+313.9%
+313.9%

More News

Read More
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
Revolution Medicines Inc (NASDAQ:RVMD) Q1 2026 Loss Widens Amid Clinical Promise ↗
Via Chartmill
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Via The Motley Fool
News headline image
This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake ↗
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares ↗
Via The Motley Fool
News headline image
Revolution (RVMD) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems ↗
Via The Motley Fool
News headline image
Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)
Via Finterra
Topics Initial Public Offering
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
From Revolution Medicines, Inc.
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Via The Motley Fool
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?
Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.
What exchange does Revolution Medicines, Inc. - Common Stock trade on?
Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?
The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market
What is the current price of Revolution Medicines, Inc. - Common Stock?
The current price of Revolution Medicines, Inc. - Common Stock is 165.71
When was Revolution Medicines, Inc. - Common Stock last traded?
The last trade of Revolution Medicines, Inc. - Common Stock was at 06/22/26 12:44 PM ET
What is the market capitalization of Revolution Medicines, Inc. - Common Stock?
The market capitalization of Revolution Medicines, Inc. - Common Stock is 17.62B
How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?
Revolution Medicines, Inc. - Common Stock has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.